135481-57-1

Usage

Uses

Due to the limited information available on 6-Benzyl-5,6,7,8-tetrahydro-1H-pyrido[4,3-d]pyrimidine-2,4-dione, its specific applications are not clearly defined. However, given its classification as a tetrahydro-1H-Pyrido[4,3-d]pyrimidine, it may have potential uses in various industries, such as:
Used in Pharmaceutical Industry:
6-Benzyl-5,6,7,8-tetrahydro-1H-pyrido[4,3-d]pyrimidine-2,4-dione could be used as a chemical intermediate for the synthesis of pharmaceutical compounds, given its complex molecular structure and the presence of benzyl groups. Its potential role in drug development may be explored further through research and experimentation.
Used in Chemical Research:
As a member of the tetrahydro-1H-Pyrido[4,3-d]pyrimidines family, 6-Benzyl-5,6,7,8-tetrahydro-1H-pyrido[4,3-d]pyrimidine-2,4-dione may be utilized in chemical research to study its properties, reactivity, and potential applications in various chemical reactions.

InChI:InChI=1/C14H15N3O2/c18-13-11-9-17(8-10-4-2-1-3-5-10)7-6-12(11)15-14(19)16-13/h1-5H,6-9H2,(H2,15,16,18,19)

Upstream product

• 57-13-6 urea 
• 159660-85-2 1-benzyl-4-aminotetrahydropyridine-3-carboxylic acid methyl ester 
• 111-94-4 3,3'-Iminodipropionitrile 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 57611-47-9 1-benzyl-4-oxo-piperidine-3-carboxylic acid methyl ester 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 14247-04-2 4-amino-1-benzyl-1.2.5.6-tetrahydropyridine-3-carbonitrile 
• 100-39-0 benzyl bromide 
• 782-87-6 N-benzylbis(2-cyanoethyl)amine 
• 67140-12-9 6-benzyl-2-thioxo-2,3,5,6,7,8-hexahydro-1H-pyrido<4,3-d>pyrimidin-4-one 
• 135481-54-8 4-ethoxy-5,6,7,8-tetrahydro-6-(phenylmethyl)-pyrido<4,3-d>pyrimidin-2(1H)-one 

Downstream Products

• 635698-66-7 6-Benzyl-2,4-dibromo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1207358-07-3 C₂₅H₃₄N₆O₄ 
• 1207358-19-7 C₂₄H₂₈N₈O₂ 
• 1208901-69-2 2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrochloride 
• 1207358-03-9 C₂₀H₂₆N₆O₂ 
• 1207358-49-3 C₂₆H₃₆N₆O₄ 
• 1207358-51-7 C₂₁H₂₈N₆O₂ 
• 1542711-17-0 N-tert-butyl 4-(benzylamino)-2-chloro-7,8-dihydropyrido-[4,3-d]pyrimidine-6(5H)-carboxylate 
• 1542711-20-5 C₂₈H₃₁N₅O₂ 
• 1542704-38-0 N-benzyl-2-(2-methyl-1H-indol-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 778574-06-4 6-benzyl-2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-d]-pyrimidine 
• 1201781-22-7 2,4-dichloro-6-(1-chloroethoxycarbonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 

Relevant academic research and scientific papers

NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula: wherein R1, R2 and R3 are as described herein, compositions including the compounds and methods of using the compounds.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90

Heat shock protein 90 (Hsp90) is a potential target for oncology therapeutics. Some inhibitors have shown antitumor effects in clinical trials, spurring the discovery of small molecule Hsp90 inhibitors. Here, we describe the structural optimization studies of a hit compound, tetrahydropyrido[4,3-d]pyrimidine-based Hsp90 inhibitor 15, which exhibits inhibitory activity against Hsp90. A series of analogues were synthesized, and their structure-activity and structure-property relationships were analyzed. These explorations led to the discovery of compound 73, which exhibited potent in vitro activities, good physicochemical properties, favorable ADME properties, and a potent antitumor effect in an HCT116 xenograft model. Furthermore, 73 exhibited no ocular toxicity in a rat retinal damage model, suggesting it is a relatively safe Hsp90 inhibitor. As a promising antitumor agent, 73 was progressed for further preclinical evaluation.

Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening

Rapid Overlay of Chemical Structures (ROCS), which can rapidly identify potentially active compounds by shape comparison, is recognized as a powerful virtual screening tool. By ROCS, a class of novel Hsp90 inhibitors was identified. The calculated binding mode of the most potent hit 36 guided us to design and synthesize a series of analogs (57a-57h). Over 100-fold improvement was achieved in the target-based assay. The most potent compound 57h inhibited Hsp90 with IC50 0.10 ± 0.01 μM. It also showed much improved cell potency and ligand efficiency. Our study showed that ROCS is efficient in the identification of novel cores of Hsp90 inhibitors. 57h can be ideal leads for further optimization.

FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity

Selective inhibitors of mammalian target of rapamycin (mTOR) kinase based upon saturated heterocycles fused to a pyrimidine core were designed and synthesized. Each series produced compounds with Ki 500-fold sel

PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR ASTHMA

The present invention provides an agent for prevention and/or treatment of asthma comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides an agent for prevention and/or treatment of asthma which comprises a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents a substituted or unsubstituted lower alkyl, or the like; R2 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, or the like; n represents 0 or 1; X represents -(CH2)2-, or the like; and Y represents the formula (II) (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, a substituted or unsubstituted lower alkyl, or the like; and Z3 represents hydrogen, a substituted or unsubstituted lower alkyl, or the like)] as an active ingredient.

PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR ITCH

The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents substituted or unsubstituted lower alkyl, etc.; R2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents -(CH2)2-, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.)]

BICYCLIC PYRIMIDINE DERIVATIVES

[wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m + n is 4 or less; R1 represents NR4R5 (wherein R4 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, -C(=O)-, -SO2-, -OC(=O)- or the like; and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like]ψBicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.